GB2239600A - Ibuprofen triturates and topical compositions containing same - Google Patents

Ibuprofen triturates and topical compositions containing same Download PDF

Info

Publication number
GB2239600A
GB2239600A GB9020874A GB9020874A GB2239600A GB 2239600 A GB2239600 A GB 2239600A GB 9020874 A GB9020874 A GB 9020874A GB 9020874 A GB9020874 A GB 9020874A GB 2239600 A GB2239600 A GB 2239600A
Authority
GB
United Kingdom
Prior art keywords
ibuprofen
composition
menthol
weight
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9020874A
Other versions
GB9020874D0 (en
Inventor
John Francis Smith
Donald Peter Vaughan
Kenneth Murray Henderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mentholatum Co Ltd
Original Assignee
Mentholatum Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mentholatum Co Ltd filed Critical Mentholatum Co Ltd
Publication of GB9020874D0 publication Critical patent/GB9020874D0/en
Publication of GB2239600A publication Critical patent/GB2239600A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Ibuprofen forms a co-solution mixture which can be admixed with a vehicle to form a stable topical composition. Part of the menthol can be replaced by benzyl alcohol and the mixture can comprise also a pharmacologically acceptable alcohol, especially propylene glycol.

Description

IBUPROFEN TRITURATES AND TOPICAL COMPOSITIONS CONTAINING SAME The present invention relates to topical ibuprofen formulations.
Ibuprofen (ie. (isobutyl phenyl)propionic acid) is a white crystalline drug, insoluble in water but relatively soluble in organic solvents such as alcohol (1 in 1.5); chloroform (1 in 1); ether (1 in 2) and acetone (1 in 1.5).
Ibuprofen usually is taken orally and, although a number of topical formulations have been proposed, we are not aware of any satisfactory topical formulations.
However, it often would be preferred to administer ibuprofen by topical application to an affected area so as to permit absorption through the skin. For example, in the treatment of rheumatic pain and/or inflammation, it is desirable to sustain a high local concentration of ibuprofen in the affected area of the body. Whereas oral administration to provide such local concentration would result in unacceptably high concentrations of ibuprofen throughout the body, topical application allows ibuprofen to accumulate only where it is needed.
In this connection, it is believed that solution dosage forms offer the best prospects of efficient percutaneous absorption of ibuprofen from topical formulations.
The present Applicants have experimented with topical formulations using conventional vehicles containing long chain cetyl and stearyl alcohols. They found that ibuprofen appears to react with these alcohols, thus reducing the concentration of the active ingredient for absorption. There was also a marked tendency for the ibuprofen to crystallise on storage as described above.
Mineral and vegetable oils dissolve ibuprofen but, even at very high oil concentrations, the ibuprofen soon crystallises out. Oleic acid also dissolves ibuprofen but the solution has an unpleasant smell and is sticky and liable to autoxidation.
Vehicles based on combinations of oleic acid and medium chain length oils were investigated with various emulsifying agents - but avoiding cetyl and stearyl alcohols. These combinations prevented ibuprofen from crystallising out of an organic solution, but the emulsion formed could not be stiffened or settled sufficiently to withstand storage at 35 to 370C for several months.
Further, the H.L.B. (ie. hydrophilic-lipophilic balance) was higher than considered desirable for topical use.
Menthol (ie. 2-isopropyl-5-methylcyclohexanol) is a crystalline, naturally-occurring substance which has been used in pharmacy for at least a century. It has a penetrating odour and, for that reason, is widely used to relieve symptoms of bronchitis, sinusitis and similar conditions. It is used as an adjuvant in a number of topical formulations and has been reported to enhance the percutaneous transfer of systemically active, watersoluble or solubilizable drugs (see EP-A-0147146).
It has long been known that trituration of menthol with certain other crystalline substances, such as camphor (ie. 1,7,7-trimethylbicyclo(2,2,1)heptan-2-one), chloral hydrate (ie. 2,2,2-trichloroethane-1,1-diol) and phenol, forms a co-solution liquid or soft mass. However, we are not aware of any disclosure of trituration or admixture of menthol with a propionic acid derivative or of any other disclosure which would have led those skilled in the art of topical formulations to consider the use of menthol to overcome the problem of topically formulating ibuprofen.
JP-A-63179820 discloses that the bioavailability of water-soluble pharmacological agents in suppository preparations can be increased by adding the agent to the suppository base as a solution in a mixture of menthol and camphor. Ibuprofen is included in the list of specified agents.
It has now surprisingly been found that ibuprofen and menthol (both crystalline substances) form a co-solution when mixed together. Whilst not wishing to be bound to any particular theory, it is believed that the two substances form a co-solution or eutectic solution when so mixed. Depending upon the relative proportions of the two components, one or both may be present partially in microcrystalline form.
The use of such a co-solution in a topical pharmaceutical composition leads to improved stability.
Further, co-solution mixtures of ibuprofen and menthol can be formed in situ by mixing ibuprofen and menthol together with other components of a topical composition.
It also has been found that the amount of menthol required to provide a co-solution with ibuprofen can be reduced by the presence of benzyl alcohol as a co-solvent for the ibuprofen.
The present invention provides a composition comprising a co-solution mixture of ibuprofen and menthol.
The invention further provides a topical pharmaceutical composition containing said mixture in a pharmacologically acceptable vehicle and the use of menthol to stabilize a topical composition comprising ibuprofen.
A liquid triturate can be formed by triturating the ibuprofen, menthol and optionally other components at ambient temperature and the triturate added to a vehicle to form the topical pharmaceutical composition of the invention. However, the triturate could be formed by heating the components together whilst triturating or by stirring or otherwise mixing a fused mass of the components and then cooling the hot mixture.
Alternatively, the components can be compounded by dissolution in a suitable solvent, such as ethanol and the resultant solution (containing the co-solution mixture) added to the vehicle.
Any relative proportions of ibuprofen and menthol which provide a co-solution mixture which is liquid at ambient temperature can be used. Suitably, the amount of ibuprofen by weight will be 10 to 70 percent based upon the weight of said mixture. However, said amount of ibuprofen preferably is 50 to 70 percent by weight.
Part of the menthol can be replaced by benzyl alcohol. When benzyl alcohol is present, it usually will replace 10 to 80, preferably 25 to 60, weight percent of the menthol.
It is preferred to include a pharmaceutically acceptable alcohol, especially a glycol such as propylene glycol or a Macrogol (ie. polyethylene glycol) in the liquid triturate of the invention when it is to be used to formulate a topical gel. When a triturate contains a glycol, it usually will be present in an amount by weight of up to 30 percent of the triturate. Preferably, said amount is 10 to 30 percent by weight and especially 20 to 25 percent by weight. However, substantially more glycol, eg. up to 70 percent by weight of the combined weight of ibuprofen, menthol, glycol and, if present, benzyl alcohol can be used when formulating a topical composition via a solution as mentioned above.
The liquid triturate or other co-solution mixture can be admixed with any compatible pharmacologically acceptable vehicle to form a topical composition.
Preferably, the vehicle is an aqueous gel or cream.
Carbomer (ie. carboxypolymethylene; carboxyvinyl polymer) is particularly suitable as a gelling agent in said aqueous gel vehicle.
Usually, the concentration of ibuprofen in the topical compositions of the invention will be in the range 0.1 to 20 percent by weight but any pharmacologically active concentration can be used. Preferably, the ibuprofen concentration will be 2 to 12 percent by weight and especially 3 to 6 percent by weight. Said amounts are by weight based upon the total weight of the topical composition.
The topical compositions of the invention can contain other compatible pharmacologically acceptable additives conventionally used in topical formulations such as antimicrobial agents, colorants, perfumes, Ph modifiers, antioxidants and stabilisers. Further, they can contain other compatible pharmacologically active substances such as other non-steroidal anti-inflammatory agents, steroids, antibiotics and antibacterials.
The present invention is illustrated by the following non-limiting examples.
EXAMPLE 1 4 g Crystalline ibuprofen was triturated with 4 g crystalline menthol to form an oil phase. This oil phase was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition: Ibuprofen 4 g Menthol 4 g Carbomer* 1-2 g Ethanol qs Water to 100 g * Carbopol 941 EXAMPLE 2 4 g Crystalline ibuprofen was triturated with 4 g crystalline menthol and 5 g propylene glycol to form an oil phase, which was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition:: Ibuprofen 4 g Menthol 4 g Propylene glycol 5 g Carbomer* 1-2 g Ethanol qs Water to 100 g * Carbopol 941 EXAMPLE 3 4 g Crystalline ibuprofen was triturated with 4 g crystalline menthol, 3 g propylene glycol and 3 g benzyl alcohol to form an oil phase, which was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition.
Ibuprofen 4 g Menthol 4 g Propylene glycol 3 g Benzyl alcohol 3 g Carbomer* 1-2 g Ethanol qs Water to 100 g * Carbopol 941 EXAMPLE 4 4 g Crystalline ibuprofen was triturated with 2 g crystalline menthol, 4 g propylene glycol and 4 g benzyl alcohol to form an oil phase, which was then mixed with Carbomer, ethanol and water to form a topical gel having the following composition.
Ibuprofen 4 g Menthol 2 g Propylene glycol 4 g Benzyl alcohol 4 g Carbomer* 1-2 g Ethanol qs Water to 100 g * Carbopol 941 EXAMPLE 5 3.0 g Crystalline ibuprofen was triturated with 1.5 crystalline menthol to form an oil phase. This oil phase was then mixed with propylene glycol and then added to a second gel of Carbomer, ethanol and water to form a topical gel having the following composition: Ibuprofen 3.0 g Menthol 1.5 g Propylene glycol 6.7 g Carbomer* 1-2 g Triethanolamine (85%) 1.25 g Ethanol 23.0 g Water to 100 g * Carbopol 980 The gel was cloudy in appearance and, under the microscope was seen to contain dispersed microcrystalline material.
EXAMPLE 6 Ibuprofen, menthol and propylene glycol were mixed together in ethanol and the resultant solution mixed with an aqueous Carbomer gel and subsequently thickened with triethanolamine to provide a topical gel of the same composition as that of Example 5.
The gels of Examples 1 to 6 were found to be completely stable after storage for 6 months at ambient temperatures. At the end of the period of storage there was no significant loss of dissolved ibuprofen through crystallisation.

Claims (24)

CLAIMS:
1. A composition comprising a co-solution mixture of ibuprofen and menthol.
2. A topical pharmaceutical composition comprising a cosolution mixture of ibuprofen and menthol in a pharmacologically acceptable vehicle.
3. A topical composition as claimed in Claim 2, wherein the vehicle is an aqueous gel.
4. A topical composition as claimed in Claim 2 or Claim 3, wherein the ibuprofen content is 2 to 12 percent by weight of the composition.
5. A topical composition as claimed in Claim 4, wherein said ibuprofen content is 3 to 6 percent by weight of the composition.
6. A composition as claimed in Claim 1, which is a liquid triturate consisting essentially of ibuprofen and menthol.
7. A composition as claimed in any one of Claims 1 to 5, comprising benzyl alcohol.
8. A composition as claimed in Claim 7, which is a liquid triturate consisting essentially of ibuprofen, menthol and benzyl alcohol.
9. A composition as claimed in Claim 7 or Claim 8, wherein the ratio by weight of benzyl alcohol to menthol is 1:3 to 3:2.
10. A composition as claimed in Claim 9, wherein benzyl alcohol and menthol are in equal parts by weight.
11. A composition as claimed in any one of the preceding claims, wherein the ibuprofen is present in an amount in the range 50 to 70 percent by weight of the combined weights of ibuprofen, menthol and, if present, benzyl alcohol.
12. A composition as claimed in any one of Claims 1 to 5, 7, 9, 10, and 11, further comprising at least one other pharmacologically acceptable alcohol.
13. A composition as claimed in Claim 12, comprising a glycol.
14. A composition as claimed in Claim 13, wherein said glycol is propylene glycol.
15. A composition as claimed in Claim 14, which is a liquid triturate consisting essentially of ibuprofen, menthol and propylene glycol.
16. A composition as claimed in Claim 14, which is a liquid triturate consisting essentially of ibuprofen, menthol, propylene glycol and benzyl alcohol.
17. A composition as claimed in any one of Claims 13 to 16, wherein the glycol is present in an amount in the range 10 to 70 percent by weight of the combined weights of ibuprofen, menthol, glycol and, if present, benzyl alcohol.
18. A composition as claimed in Claim 17, wherein the amount by weight of glycol is 10 to 30 percent by weight of the triturate.
19. A composition as claimed in any one of Claims 12 to 18, comprising ethanol.
20. The use of menthol to stabilize a topical composition comprising ibuprofen.
21. A liquid triturate as claimed in Claim 1 and substantially as hereinbefore described in Example 1.
22. A liquid triturate as claimed in Claim 15 and substantially as hereinbefore described in Example 2.
23. A liquid triturate as claimed in Claim 16 and substantially as hereinbefore described in Example 3 or Example 4.
24. A topical pharmaceutical composition as claimed in Claim 2 and substantially as hereinbefore described in any one of the Examples.
GB9020874A 1989-09-26 1990-09-25 Ibuprofen triturates and topical compositions containing same Withdrawn GB2239600A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898921710A GB8921710D0 (en) 1989-09-26 1989-09-26 Ibuprofen triturates and topical compositions containing same

Publications (2)

Publication Number Publication Date
GB9020874D0 GB9020874D0 (en) 1990-11-07
GB2239600A true GB2239600A (en) 1991-07-10

Family

ID=10663631

Family Applications (2)

Application Number Title Priority Date Filing Date
GB898921710A Pending GB8921710D0 (en) 1989-09-26 1989-09-26 Ibuprofen triturates and topical compositions containing same
GB9020874A Withdrawn GB2239600A (en) 1989-09-26 1990-09-25 Ibuprofen triturates and topical compositions containing same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB898921710A Pending GB8921710D0 (en) 1989-09-26 1989-09-26 Ibuprofen triturates and topical compositions containing same

Country Status (6)

Country Link
EP (1) EP0493496A1 (en)
JP (1) JPH05502440A (en)
AU (1) AU6504190A (en)
CA (1) CA2067131A1 (en)
GB (2) GB8921710D0 (en)
WO (1) WO1991004733A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1222932A1 (en) * 1999-10-14 2002-07-17 Pola Chemical Industries, Inc. Compositions for electroporation
EP1222930A1 (en) * 1999-10-14 2002-07-17 Pola Chemical Industries, Inc. Compositions for electroporation
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360938A (en) * 1991-08-21 1994-11-01 Union Carbide Chemicals & Plastics Technology Corporation Asymmetric syntheses
DE4446600A1 (en) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermal absorption of active ingredients from supercooled melts
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
AT408067B (en) * 1995-03-17 2001-08-27 Gebro Pharma Gmbh PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION AND METHOD FOR THE PRODUCTION THEREOF
CA2289966A1 (en) 1997-05-14 1998-11-19 Galen (Chemicals) Limited Topical compositions
US6299902B1 (en) 1999-05-19 2001-10-09 The University Of Georgia Research Foundation, Inc. Enhanced transdermal anesthesia of local anesthetic agents
US6368618B1 (en) * 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
PT1487416E (en) * 2002-03-26 2010-01-25 Teva Pharma Drug microparticles
JP2005350379A (en) * 2004-06-09 2005-12-22 Ikeda Mohandou:Kk Method for stabilizing prednisolone valerate acetate and excellently stable skin care preparation for external use comprising prednisolone valerate acetate
US20130072575A1 (en) * 2011-09-19 2013-03-21 Johnson & Johnson Consumer Companies, Inc. Method and Composition for Treating Pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
EP0147146A2 (en) * 1983-12-22 1985-07-03 American Home Products Corporation Enhancement of transdermal drug delivery
JPS63179820A (en) * 1987-01-22 1988-07-23 Kao Corp Suppository composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815909A (en) * 1981-07-22 1983-01-29 Toko Yakuhin Kogyo Kk Antimycotic agent for external use
JPS5829706A (en) * 1981-08-14 1983-02-22 Toko Yakuhin Kogyo Kk Antiphlogistic and analgesic agent for external use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
EP0147146A2 (en) * 1983-12-22 1985-07-03 American Home Products Corporation Enhancement of transdermal drug delivery
JPS63179820A (en) * 1987-01-22 1988-07-23 Kao Corp Suppository composition

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1222932A1 (en) * 1999-10-14 2002-07-17 Pola Chemical Industries, Inc. Compositions for electroporation
EP1222930A1 (en) * 1999-10-14 2002-07-17 Pola Chemical Industries, Inc. Compositions for electroporation
EP1222932A4 (en) * 1999-10-14 2004-05-12 Pola Chem Ind Inc Compositions for electroporation
US7089053B1 (en) 1999-10-14 2006-08-08 Pola Chemical Industries Inc Compositions for drug administration by electroporation
EP1222930B1 (en) * 1999-10-14 2006-11-02 Pola Chemical Industries Inc. Compositions for electroporation
US7197359B1 (en) 1999-10-14 2007-03-27 Pola Chemical Industries Inc. Compositions for electroporation
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films

Also Published As

Publication number Publication date
GB8921710D0 (en) 1989-11-08
WO1991004733A1 (en) 1991-04-18
EP0493496A1 (en) 1992-07-08
AU6504190A (en) 1991-04-28
GB9020874D0 (en) 1990-11-07
JPH05502440A (en) 1993-04-28
CA2067131A1 (en) 1991-03-27

Similar Documents

Publication Publication Date Title
EP0072462B1 (en) Pharmaceutical preparations
EP0151953B1 (en) Topical drug release system
US5990100A (en) Composition and method for treatment of psoriasis
KR101793707B1 (en) Non-steroidal anti-inflammatory solution comprising diclofenac acid, lidocaine and acid stabilizer
GB2239600A (en) Ibuprofen triturates and topical compositions containing same
US4794117A (en) Process for solubilizing active ingredients and the thus-obtained pharmaceutical compositions
US20060241175A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
US20040063794A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
PL177592B1 (en) Novel composition
WO1991008733A1 (en) Stable cream and lotion bases for lipophilic drug compositions
JPS5815909A (en) Antimycotic agent for external use
JP4195178B2 (en) Anti-inflammatory analgesic topical
JPH0676328B2 (en) Steroid cream formulation
KR20020038595A (en) Topical Formulations Comprising Skin Penetration Agents and the Use Thereof
JP4066466B2 (en) Ointment containing sugar alcohols
US4602040A (en) Meclofenamic acid topical pharmaceutical composition
US5128135A (en) Percutaneous or trans-mucosal absorption enhancers, preparations containing the enhancers, and a method of preparing thereof
JPH0413624A (en) Pyroxycam-containing pharmaceutical composition for topical application
GB2236250A (en) Ibuprofen solutions and topical compositions
WO2006134406A1 (en) Stable pharmaceutical gel of diclofenac sodium
AU643975B2 (en) Pharmaceutical formulation
JPS62223118A (en) Cream composition for external use
HU226686B1 (en) Semisolid pharmaceutical formulation containing dexketoprofen trometamol
GB2327041A (en) Topical Analgesic Composition
HU224686B1 (en) Pharmaceutical composition for external use containing nimesulide and process for the preparation thereof

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)